Bio-Path Holdings, Inc. (BPTH) News
Filter BPTH News Items
BPTH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BPTH News Highlights
- BPTH's 30 day story count now stands at 2.
- Over the past 24 days, the trend for BPTH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO, PATH and BP are the most mentioned tickers in articles about BPTH.
Latest BPTH News From Around the Web
Below are the latest news stories about BIO-PATH HOLDINGS INC that investors may wish to consider to help them evaluate BPTH as an investment opportunity.
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid LeukemiaBP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 ProteinHOUSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP |
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call TranscriptBio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Following the formal remarks, we will open the call up for your questions. Please […] |
Bio-Path Holdings Reports Third Quarter 2023 Financial ResultsConference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “The third quarter marked a particularly progressive time a |
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview. To access the live c |
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid LeukemiaConference call to be held on Monday, October 30, 2023 at 9:00 a.m. ETHOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! |
Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit OutlookWith the business potentially at an important milestone, we thought we'd take a closer look at Bio-Path Holdings... |
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment ConferenceHOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET. An audio webc |
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23Dallas, Texas--(Newsfile Corp. - August 30, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2023. The full report can be accessed by clicking on the following link: BPTH Q2 23 Report To view the full announcement, including downloadable images, bios, and more, click here. ... |
Q2 2023 Bio Path Holdings Inc Earnings CallQ2 2023 Bio Path Holdings Inc Earnings Call |